{"denoms":[{"counts":[{"groupId":"BG000","value":"475"}],"units":"Participants"}],"groups":[{"description":"Participants received pembrolizumab 10 mg/kg IV over 30 minutes once every 2 weeks (Q2W) for up to \\~2 years. Qualified participants who completed the first course of pembrolizumab treatment but progressed after discontinuation were eligible for a second course of pembrolizumab at 10 mg/kg IV Q2W for up to \\~1 additional year, at the Investigator's discretion. Per protocol participants were presented by treatment received in the single arm study.","id":"BG000","title":"Pembrolizumab (MK-3475) 10 mg/kg"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"11.7","value":"58.7"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"Years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"281"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"194"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"18"}],"title":"Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"380"}],"title":"Not Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"77"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Ethnicity (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"1"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"99"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Native Hawaiian or Other Pacific Islander"},{"measurements":[{"groupId":"BG000","value":"20"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"280"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"2"}],"title":"More than one race"},{"measurements":[{"groupId":"BG000","value":"73"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race (NIH/OMB)","unitOfMeasure":"Participants"}],"populationDescription":"The analysis population consisted of all allocated participants who received at least one dose of study drug. Per protocol, Baseline Characteristics were summarized by treatment dose."}